Laboratory abnormalities in patients with COVID-2019 infection
By Giuseppe Lippi, Mario Plebani. Clinical Chemistry and Laboratory Medicine, 2020
902 citations recorded by the source corpus.
The aim of this article is to provide a brief overview on the most frequent laboratory abnormalities encountered in patients with COVID-2019 infection An electronic search was performed in Medline (PubMed interface), Scopus and Web of Science, using the keywords "2019 novel coronavirus" or "2019-nCoV"or "COVID-19" without date or language restrictions The title, abstract and full text (when available) of all articles identified according to these search criteria were scrutinized by the authors, and those describing significant laboratory abnormalities in patients with severe COVID-19 infection were finally selected The references of identified documents were also crosschecked for detecting additional studies A particular mention shall be made for procalcitonin and coagulation tests The former test does not appear substantially altered in patients with COVID-19 at admission, but the progressive increase of its value seemingly mirrors a worse prognosis This is not unexpected, whereby serum procalcitonin levels are typically normal in patients with viral infections (or viral sepsis), whilst its gradual increase probably mirrors bacterial superinfection, which may then contribute to drive the clinical course towards unfavorable progression The measurement of other innovative sepsis biomarkers, such as presepsin, for example, would probably help in increasing the accuracy in identification of severe COVID-19 cases, as well as for improving the current approach used for mortality risk prediction As concerns hemostasis tests, the evidence that laboratory criteria for diagnosing DIC are present in nearly three-fourths of patients who died underscores the critical role of these tests in this and other clinical settings, thus suggesting that their assessment shall be considered a routine part of COVID-19 patient monitoring
Subfields: Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/0d9f4366ceb7fde6cb7dc2b2fa3bb3636abb9b4d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis (2020, neutral): “Recent literature data has shown that cTnI concentration is only marginally increased in all patientswith SARS-CoV-2 infection,whereby values exceeding the 99th percentile in the upper reference limit (URL) can only be observed in 8–12% of positive cases.(10) Nonetheless, what seems to emerge from o”
- COVID-19: immunopathogenesis and Immunotherapeutics (2020, background): “Patients with severe COVID-19 are more likely to exhibit lymphopenia on admission, indicating a significant predictor for severe patients.(9,10) Patients also show a marked reduction in CD4 T, CD8 T, NK, and B cell number.”
- Detection of COVID-19 Infection from Routine Blood Exams with Machine Learning: A Feasibility Study (2020, neutral): “In [27] a comprehensive All rights reserved.”
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy (2020, neutral): “In Chinese reports, lower levels of lymphocyte count, higher levels of ferritin, LDH, transaminases and Ddimer were associated with a worse prognosis [10,11].”
- COVID-19 and diabetes: Knowledge in progress (2020, neutral): “In the current SARS-CoV-2 pandemic, some studies did not find a clear association between diabetes and severe disease [19,38].”
- Cardiovascular disease and COVID-19 (2020, background): “Table 1 The overall incidence of acute cardiac injury has been variable but roughly 8e12% of the positive cases are known to develop significant elevation of cTnI [10].”
- Prominent changes in blood coagulation of patients with SARS-CoV-2 infection (2020, background): “We hence reinforce the suggestion that routine monitoring of hemostasis tests may be a useful aid for establishing an accurate therapeutic strategy and preventing disease progression, up to death [19].”
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “55 Huang 2020 Yang 2020 Zhou et al Gao 2020 Wang 2020 Wu 2020 Tang 2020 Lippi 2020 Lippi 2020 Lippi 2020”